Is there a deleterious effect of erythropoietin in end-stage renal disease

Kidney International

Volumn 80, Issue 6, 2011, Pages 569-571

  Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTIANEMIC AGENT; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG LABELING; DRUG MEGADOSE; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIVIDUALIZATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STROKE; VENOUS THROMBOEMBOLISM;

EID: 80052224525     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.190     Document Type: Note

References (17)

1. Office of Inspector General. Medicare reimbursement for existing end-stage renal disease drugs. OEI-03-04-00120. Department of Health and Human Services, Washington, DC, 2004.
2. Anonymous. Dosing for dollars. Forbes [online] 17 April 2007 http://www.forbes.com/2007/04/17/amgen-dialysis-study-biz-cz-kd-0417amgen. html.
3. Besarab A, Bolton WK, Browne wne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)
4. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
5. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
6. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
7. Corwin HL, Gettinger A, Fabian TC et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976. (Pubitemid 47367076)
8. Stowell CP, Jones SC, Enny C et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. S pine (Phila Pa 1976) 2009; 34: 2479-2485.
9. Najjar SS, Rao SV, Melloni C et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction. REVEAL: a randomized controlled trial. J AMA 2011; 305: 1863-1872.
10. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
11. Jacques LB, Jensen TS, Rollins J et al. Proposed Decision Memo for erythropoiesis stimulating agents (ESAs) for treatment of anemia in adults with CKD including patients on dialysis and patients not on dialysis (CAG-00413N). Centers for Medicare and Medicaid Services. https://www.cms.gov/medicare- coverage-database/details/nca-proposed-decision-memo.aspx?NCA Id=245
12. Zhang Y, Thamer M, Kaufman JS et al. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 2011; 80: 663-669.
13. Bradbury BD, Wang O, Critchlow CW et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70. (Pubitemid 350296516)
14. Wang O, Kilpatrick RD, Critchlow CW et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. C lin J Am Soc Nephrol 2010; 5: 182-188.
15. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
16. Goodkin DA, Fuller DS, Robinson BM et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011; 22: 358-365.
17. Seliger SL, Zhang AD, Weir MR et al. Erythropoiesisstimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011; 80: 288-294.